pLX304_zeo_eGFP Citations (2)

Originally described in: Inactivation of Fbxw7 impairs dsRNA sensing and confers resistance to PD-1 blockade.
Gstalder C, Liu D, Miao D, Lutterbach B, DeVine AL, Lin C, Shettigar M, Pancholi P, Buchbinder EI, Carter SL, Manos MP, Rojas-Rudilla V, Brennick R, Gjini E, Chen PH, Lako A, Rodig S, Yoon CH, Freeman GJ, Barbie DA, Hodi FS, Miles W, Van Allen EM, Haq R Cancer Discov. 2020 May 5. pii: 2159-8290.CD-19-1416. doi: 10.1158/2159-8290.CD-19-1416. PubMed Journal

---

Articles Citing pLX304_zeo_eGFP

Articles
Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Lin CC, Chang TC, Wang Y, Guo L, Gao Y, Bikorimana E, Lemoff A, Fang Y, Zhang H, Zhang Y, Ye D, Soria-Bretones I, Servetto A, Lee KM, Luo X, Otto J, Akamatsu H, Napolitano F, Mani R, Cescon D, Xu L, Xie Y, Mendell J, Hanker A, Arteaga C. Res Sq. 2023 Jul 10:rs.3.rs-2966905. doi: 10.21203/rs.3.rs-2966905/v1. Preprint. PubMed
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Lin CC, Chang TC, Wang Y, Guo L, Gao Y, Bikorimana E, Lemoff A, Fang YV, Zhang H, Zhang Y, Ye D, Soria-Bretones I, Servetto A, Lee KM, Luo X, Otto JJ, Akamatsu H, Napolitano F, Mani R, Cescon DW, Xu L, Xie Y, Mendell JT, Hanker AB, Arteaga CL. Nat Commun. 2024 Mar 13;15(1):2287. doi: 10.1038/s41467-024-46495-2. PubMed

If you have published an article using this material, please email us at to have your article added to this page.